CRBU Caribou Biosciences Inc revenue, earnings and financials

For the quarter ended June 30, 2026, Caribou Biosciences Inc reported revenue of $1.50M (down 43.8% from a year earlier), net income of −$24.3M and diluted EPS of −$0.24; over the last four quarters revenue was $10.0M and net income −$103M; for the fiscal year ended December 2025 revenue was $11.2M, up 11.7% on the year before.

CRBU annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $11.2M, gross profit n/a, operating income −$148M, net income −$148M (margin -1327.4%), EPS −$1.59
• Fiscal year ended Dec 2024: revenue $9.99M, gross profit n/a, operating income −$167M, net income −$149M (margin -1491.9%), EPS −$1.65
• Fiscal year ended Dec 2023: revenue $34.5M, gross profit n/a, operating income −$116M, net income −$102M (margin -296.1%), EPS −$1.38
• Fiscal year ended Dec 2022: revenue $13.9M, gross profit n/a, operating income −$106M, net income −$99.4M (margin -717.8%), EPS −$1.64
• Fiscal year ended Dec 2021: revenue $9.60M, gross profit n/a, operating income −$67.0M, net income −$66.9M (margin -697.3%), EPS −$2.11

CRBU quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $1.50M (down 43.8% year over year), net income −$24.3M, EPS −$0.24
• Quarter ended Mar 31, 2026: revenue $2.40M (up 1.9% year over year), net income −$25.1M, EPS −$0.26
• Quarter ended Dec 31, 2025 (from the annual report): revenue $3.94M (up 89.7% year over year), net income −$26.5M, EPS −$0.28
• Quarter ended Sep 30, 2025: revenue $2.20M (up 8.6% year over year), net income −$27.5M, EPS −$0.30
• Quarter ended Jun 30, 2025: revenue $2.67M (down 23.0% year over year), net income −$54.1M, EPS −$0.58
• Quarter ended Mar 31, 2025: revenue $2.35M (down 3.1% year over year), net income −$40.0M, EPS −$0.43
• Quarter ended Dec 31, 2024 (from the annual report): revenue $2.08M (down 41.6% year over year), net income −$35.5M, EPS −$0.39
• Quarter ended Sep 30, 2024: revenue $2.02M (down 91.4% year over year), net income −$34.7M, EPS −$0.38
• Quarter ended Jun 30, 2024: revenue $3.46M (down 7.7% year over year), net income −$37.7M, EPS −$0.42
• Quarter ended Mar 31, 2024: revenue $2.43M (down 30.6% year over year), net income −$41.2M, EPS −$0.46
• Quarter ended Dec 31, 2023 (from the annual report): revenue $3.56M (down 3.6% year over year), net income −$34.5M, EPS −$0.32
• Quarter ended Sep 30, 2023: revenue $23.7M (up 616.4% year over year), net income −$10.0M, EPS −$0.12
• Quarter ended Jun 30, 2023: revenue $3.76M (down 10.4% year over year), net income −$29.5M, EPS −$0.48
• Quarter ended Mar 31, 2023: revenue $3.50M (up 31.5% year over year), net income −$28.0M, EPS −$0.46
• Quarter ended Dec 31, 2022 (from the annual report): revenue $3.69M (up 44.3% year over year), net income −$27.0M, EPS −$0.44
• Quarter ended Sep 30, 2022: revenue $3.30M (down 16.9% year over year), net income −$26.6M, EPS −$0.44
• Quarter ended Jun 30, 2022: revenue $4.19M, net income −$26.7M, EPS −$0.44
• Quarter ended Mar 31, 2022: revenue $2.66M (up 68.0% year over year), net income −$19.1M, EPS −$0.32
• Quarter ended Dec 31, 2021: revenue $2.56M, net income −$18.5M, EPS −$0.31
• Quarter ended Sep 30, 2021: revenue $3.98M, net income −$21.0M, EPS −$0.46

CRBU cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$111M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$138M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$93.3M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$91.0M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$32.5M, share buybacks n/a

CRBU balance sheet

• Jun 30, 2026: cash $26.2M, total assets $143M, total liabilities $44.7M, shareholders' equity $98.1M
• Mar 31, 2026: cash $12.1M, total assets $149M, total liabilities $47.0M, shareholders' equity $102M
• Dec 31, 2025: cash $12.4M, total assets $175M, total liabilities $53.2M, shareholders' equity $122M
• Sep 30, 2025: cash $11.1M, total assets $195M, total liabilities $53.1M, shareholders' equity $142M
• Jun 30, 2025: cash $25.2M, total assets $221M, total liabilities $54.8M, shareholders' equity $166M
• Mar 31, 2025: cash $29.4M, total assets $274M, total liabilities $56.4M, shareholders' equity $217M
• Dec 31, 2024: cash $16.3M, total assets $313M, total liabilities $60.4M, shareholders' equity $253M
• Sep 30, 2024: cash $32.0M, total assets $344M, total liabilities $63.1M, shareholders' equity $281M

What is CRBU's revenue?

Caribou Biosciences Inc reported $10.0M of revenue over its last four quarters, through June 30, 2026.

Is CRBU profitable?

No. Caribou Biosciences Inc lost $103M over the last four quarters.

What is CRBU's EPS?

Diluted earnings per share over the last four quarters were −$1.08; −$0.24 in the latest quarter.

CRBU ownership and insider trades · All stocks